Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-4079PMID 18483370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

  2007cited by this paper
• Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

  2007cited by this paper
• Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy.

  2007cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

  2003cited by this paper
• Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis.

  2003cited by this paper
• B7-H1 pathway and its role in the evasion of tumor immunity

  2003cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function.

  2001cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.

  1997cited by this paper
• Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein

  1995cited by this paper
• A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.

  1994cited by this paper

• PD-1 inhibitor in patients with minimal residual disease who failed donor lymphocyte infusion or interferon after allogeneic haematopoietic stem cell transplantation

  2025cites this paper
• Immunotherapy in Cancer its Recent Advances and Challenges

  2025cites this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cites this paper
• Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis

  2025cites this paper
• Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia

  2025cites this paper
• Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies

  2025cites this paper
• Revolutionizing cancer treatment: Exploring novel immunotherapeutics, checkpoints, bispecifics, and vaccines in development.

  2025cites this paper
• Tumor microenvironment as a novel therapeutic target for lymphoid leukemias

  2025cites this paper
• The Immune Microenvironment in Acute Myeloid Leukemia: Mechanisms of Immune Evasion and Emerging Therapeutic Strategies

  2025cites this paper
• Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche

  2024cites this paper
• Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study

  2024influential citation
• Evolution of natural killer cell-targeted therapy for acute myeloid leukemia

  2024cites this paper
• Engineering nanoparticles for cancer immunotherapy: Current achievements, key considerations and future perspectives

  2024cites this paper
• Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia

  2024cites this paper
• Rare giant epithelioid inflammatory myofibroblastic sarcoma of the abdominal cavity in a child: a case report and review of the literature

  2024cites this paper
• Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia.

  2024cites this paper
• Inflammation as a driver of hematological malignancies

  2024cites this paper
• Dysgerminomas: germ cell tumors exhibit high expression of PD-L1 and associated with high TILs and good prognosis

  2024cites this paper
• Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia

  2023cites this paper
• TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently

  2023cites this paper
• Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumors.

  2023cites this paper
• The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions.

  2023cites this paper
• Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes.

  2023cites this paper
• Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy

  2023cites this paper
• Cyclic adenosine monophosphate potentiates immune checkpoint blockade therapy in acute myeloid leukemia

  2023cites this paper
• Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?

  2023cites this paper
• Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia

  2023cites this paper
• A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia

  2023cites this paper
• Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

  2023cites this paper
• An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

  2023cites this paper
• Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.

  2023cites this paper
• Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé

  2022cites this paper
• Perspectives on the role of breast cancer susceptibility gene in breast cancer

  2022cites this paper
• Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.

  2022cites this paper
• Cancer vaccines: the next immunotherapy frontier

  2022cites this paper
• Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia

  2022cites this paper
• Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer

  2022cites this paper
• New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy

  2022influential citation
• RNA and RNA Derivatives: Light and Dark Sides in Cancer Immunotherapy

  2022cites this paper
• Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials

  2022cites this paper
• Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy

  2022cites this paper
• Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

  2022cites this paper
• Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic

  2022influential citation
• New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes

  2022influential citation
• Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

  2022cites this paper
• Comprehensive Analysis of CRIP1 Expression in Acute Myeloid Leukemia

  2022cites this paper
• Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes

  2022influential citation
• Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives

  2022cites this paper
• The genetics of myelodysplastic syndromes and the opportunities for tailored treatments

  2022cites this paper
• Systematic analysis of prognostic and immunologic characteristics associated with coronavirus disease 2019 regulators in acute myeloid leukemia

  2022cites this paper
• A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules

  2021cites this paper
• Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment

  2021cites this paper
• Immunotherapy in AML: a brief review on emerging strategies

  2021cites this paper
• Acute Myeloid Leukemia: Is It T Time?

  2021cites this paper
• Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.

  2021cites this paper
• Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma

  2021cites this paper
• Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies

  2021cites this paper
• PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity

  2021cites this paper
• T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments

  2021cites this paper
• Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance

  2021cites this paper
• Redirecting the Immune Microenvironment in Acute Myeloid Leukemia

  2021cites this paper
• Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD

  2021cites this paper
• Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms.

  2021cites this paper
• Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy

  2021cites this paper
• PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements

  2021cites this paper
• Acute Leukemias

  2021cites this paper
• Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies.

  2021cites this paper
• The Next Decade of Immune Checkpoint Therapy.

  2021cites this paper
• Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia

  2021cites this paper
• An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!

  2021cites this paper
• Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1

  2021cites this paper
• Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing

  2021cites this paper
• Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia

  2021cites this paper
• The Landscape of Checkpoint Inhibition in the Management of Hematological Malignancies

  2021influential citation
• Divergent fates of antigen-specific CD8+ T cell clones in mice with acute leukemia

  2021cites this paper
• Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia

  2021cites this paper
• PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow

  2021cites this paper
• Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials.

  2021cites this paper
• Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis

  2021cites this paper
• TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: case reports.

  2021cites this paper
• Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia

  2021cites this paper
• PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome

  2021cites this paper
• Review of applications of CRISPR-Cas9 gene-editing technology in cancer research

  2021cites this paper
• Mechanisms of immune checkpoint inhibitor-mediated liver injury

  2021cites this paper
• Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis

  2020cites this paper
• Cancer Immunotherapy Confers a Global Benefit

  2020cites this paper
• Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways.

  2020cites this paper
• Recent Advances in the Use of NK Cells Against Cancer

  2020cites this paper
• Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!

  2020cites this paper
• Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.

  2020cites this paper
• Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma

  2020cites this paper
• The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies

  2020cites this paper
• Mechanisms of Resistance to Checkpoint Blockade Therapy.

  2020cites this paper
• Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

  2020cites this paper
• Recent developments in cancer therapy and diagnosis

  2020cites this paper
• Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment

  2020cites this paper
• Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.

  2020cites this paper
• A small-sized protein binder specific for human PD-1 effectively suppresses the tumour growth in tumour mouse model

  2020cites this paper
• Therapeutic Antibodies and Immunologic Conjugates

  2020cites this paper
• Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma

  2020cites this paper